CN101225374A - 红景天及红景天苷在干细胞定向分化为肝系细胞中的应用 - Google Patents
红景天及红景天苷在干细胞定向分化为肝系细胞中的应用 Download PDFInfo
- Publication number
- CN101225374A CN101225374A CNA2008100595168A CN200810059516A CN101225374A CN 101225374 A CN101225374 A CN 101225374A CN A2008100595168 A CNA2008100595168 A CN A2008100595168A CN 200810059516 A CN200810059516 A CN 200810059516A CN 101225374 A CN101225374 A CN 101225374A
- Authority
- CN
- China
- Prior art keywords
- cell
- rhodioside
- stem cells
- application
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 17
- 230000004069 differentiation Effects 0.000 title claims description 17
- 210000003494 hepatocyte Anatomy 0.000 title abstract description 6
- ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Natural products OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 title description 2
- 235000014327 Sedum acre Nutrition 0.000 title description 2
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 title description 2
- 240000005319 Sedum acre Species 0.000 title 1
- 241001165494 Rhodiola Species 0.000 claims abstract description 36
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 claims abstract description 34
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 claims abstract description 34
- 230000001939 inductive effect Effects 0.000 claims abstract description 29
- 239000003102 growth factor Substances 0.000 claims abstract description 20
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims abstract description 19
- 230000010261 cell growth Effects 0.000 claims abstract description 14
- 210000004504 adult stem cell Anatomy 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 43
- 210000004271 bone marrow stromal cell Anatomy 0.000 claims description 19
- 210000004185 liver Anatomy 0.000 claims description 18
- 230000006698 induction Effects 0.000 claims description 17
- 239000002609 medium Substances 0.000 claims description 14
- 210000001185 bone marrow Anatomy 0.000 claims description 12
- 210000005229 liver cell Anatomy 0.000 claims description 12
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 claims description 11
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 10
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 9
- 210000002966 serum Anatomy 0.000 claims description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical class [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 8
- 244000309466 calf Species 0.000 claims description 8
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 8
- 229930182555 Penicillin Natural products 0.000 claims description 7
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 7
- 229940049954 penicillin Drugs 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 5
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 claims description 5
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 4
- 229960003957 dexamethasone Drugs 0.000 claims description 4
- 229910052742 iron Inorganic materials 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 229910052711 selenium Inorganic materials 0.000 claims description 4
- 239000011669 selenium Substances 0.000 claims description 4
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 239000006143 cell culture medium Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 12
- 208000019423 liver disease Diseases 0.000 abstract description 7
- 230000001154 acute effect Effects 0.000 abstract description 5
- 231100000012 chronic liver injury Toxicity 0.000 abstract description 5
- 150000001875 compounds Chemical class 0.000 abstract description 5
- 238000011160 research Methods 0.000 abstract description 4
- 239000002547 new drug Substances 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 238000009509 drug development Methods 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract description 2
- 238000002054 transplantation Methods 0.000 abstract description 2
- 244000042430 Rhodiola rosea Species 0.000 abstract 3
- 235000003713 Rhodiola rosea Nutrition 0.000 abstract 3
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000000411 inducer Substances 0.000 abstract 1
- 206010067125 Liver injury Diseases 0.000 description 8
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 231100000439 acute liver injury Toxicity 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229920002527 Glycogen Polymers 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 241000220284 Crassulaceae Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000003995 blood forming stem cell Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000001700 mitochondrial membrane Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000011476 stem cell transplantation Methods 0.000 description 2
- 230000001550 time effect Effects 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000002070 Transferrins Human genes 0.000 description 1
- 108010015865 Transferrins Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 208000008445 altitude sickness Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002745 epiphysis Anatomy 0.000 description 1
- 210000002782 epithelial mesenchymal cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000009288 screen filtration Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100595168A CN101225374B (zh) | 2008-01-25 | 2008-01-25 | 红景天及红景天苷在干细胞定向分化为肝系细胞中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100595168A CN101225374B (zh) | 2008-01-25 | 2008-01-25 | 红景天及红景天苷在干细胞定向分化为肝系细胞中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101225374A true CN101225374A (zh) | 2008-07-23 |
CN101225374B CN101225374B (zh) | 2010-08-11 |
Family
ID=39857580
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008100595168A Expired - Fee Related CN101225374B (zh) | 2008-01-25 | 2008-01-25 | 红景天及红景天苷在干细胞定向分化为肝系细胞中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101225374B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102988459A (zh) * | 2011-09-16 | 2013-03-27 | 上海中医药大学附属曙光医院 | 红景天苷在制备抑制肝星状细胞迁移的药物中的应用 |
CN103045531A (zh) * | 2011-10-14 | 2013-04-17 | 北京清美联创干细胞科技有限公司 | 人参皂苷Rd诱导间充质干细胞体外定向分化成肝细胞 |
CN107496456A (zh) * | 2017-09-19 | 2017-12-22 | 青岛瑞思德生物科技有限公司 | 人脂肪间充质干细胞抗肝纤维化注射液及其制备方法 |
CN108849857A (zh) * | 2018-07-20 | 2018-11-23 | 吉林济惠生物科技有限公司 | 一种脐带间充质干细胞的运输保护液 |
CN109294980A (zh) * | 2018-10-15 | 2019-02-01 | 雷桅 | 红景天及红景天苷在干细胞定向分化为心肌样细胞中的应用 |
CN109929883A (zh) * | 2019-04-02 | 2019-06-25 | 烟台华康荣赞生物科技有限公司 | 重组酵母、构建方法和其在制备酪醇及衍生物中的应用 |
CN110841104A (zh) * | 2019-10-24 | 2020-02-28 | 广东医科大学 | 一种红景天苷-胶原蛋白海绵支架的制备方法及在皮肤创伤修复的应用 |
-
2008
- 2008-01-25 CN CN2008100595168A patent/CN101225374B/zh not_active Expired - Fee Related
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102988459A (zh) * | 2011-09-16 | 2013-03-27 | 上海中医药大学附属曙光医院 | 红景天苷在制备抑制肝星状细胞迁移的药物中的应用 |
CN103045531A (zh) * | 2011-10-14 | 2013-04-17 | 北京清美联创干细胞科技有限公司 | 人参皂苷Rd诱导间充质干细胞体外定向分化成肝细胞 |
CN107496456A (zh) * | 2017-09-19 | 2017-12-22 | 青岛瑞思德生物科技有限公司 | 人脂肪间充质干细胞抗肝纤维化注射液及其制备方法 |
CN108849857A (zh) * | 2018-07-20 | 2018-11-23 | 吉林济惠生物科技有限公司 | 一种脐带间充质干细胞的运输保护液 |
CN109294980A (zh) * | 2018-10-15 | 2019-02-01 | 雷桅 | 红景天及红景天苷在干细胞定向分化为心肌样细胞中的应用 |
CN109294980B (zh) * | 2018-10-15 | 2021-07-20 | 雷桅 | 红景天及红景天苷在干细胞定向分化为心肌样细胞中的应用 |
CN109929883A (zh) * | 2019-04-02 | 2019-06-25 | 烟台华康荣赞生物科技有限公司 | 重组酵母、构建方法和其在制备酪醇及衍生物中的应用 |
CN110841104A (zh) * | 2019-10-24 | 2020-02-28 | 广东医科大学 | 一种红景天苷-胶原蛋白海绵支架的制备方法及在皮肤创伤修复的应用 |
CN110841104B (zh) * | 2019-10-24 | 2021-10-08 | 广东医科大学 | 一种红景天苷-胶原蛋白海绵支架的制备方法及在皮肤创伤修复的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101225374B (zh) | 2010-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101225374B (zh) | 红景天及红景天苷在干细胞定向分化为肝系细胞中的应用 | |
CN103087984B (zh) | 一种具有促进间充质干细胞增殖作用的中药组合物及其应用 | |
CN109294980B (zh) | 红景天及红景天苷在干细胞定向分化为心肌样细胞中的应用 | |
CN103494865A (zh) | 人源干细胞与绞股蓝生物活性物质组合物及其制备方法 | |
CN105434482B (zh) | 一种雪松松针总黄酮的富集方法及其在抗肿瘤中的应用 | |
CN103045531A (zh) | 人参皂苷Rd诱导间充质干细胞体外定向分化成肝细胞 | |
CN105920064A (zh) | 以西洋参茎叶为原料提取分离出的天然活性成分及其应用 | |
CN102007110B (zh) | 用于预防、治疗骨健康相关疾病的黄酮醇化合物、榆树的生物活性提取物/级分及其化合物 | |
CN108795852A (zh) | 一种人肌母细胞外泌体的制备方法、产品及其应用 | |
CN103254302A (zh) | 从毛蚶中分离制备一种抗肿瘤多肽化合物的方法和用途 | |
CN115212243A (zh) | 淫羊藿提取物的应用 | |
CN104983816B (zh) | 一种牡丹皮提取物及其在制备防治肺纤维化药物中的用途 | |
Mou et al. | Anti‐hepatitis B virus activity and hepatoprotective effect of des (rhamnosyl) verbascoside from Lindernia ruellioides in vitro | |
CN105907715A (zh) | 一种日本血吸虫虫卵抗原刺激树突状细胞来源的外泌体及其应用 | |
CN109735570A (zh) | Xist修饰的脂肪来源间充质干细胞外泌体的制备及其应用 | |
CN102140439A (zh) | 大黄鱼脂肪细胞体外培养方法 | |
CN101708189B (zh) | 一种鳖甲抗肝纤维化提取物的制备方法 | |
CN103739690A (zh) | 从魁蚶中分离制备一种抗肿瘤多肽化合物的方法和用途 | |
CN108210518B (zh) | 脐带间充质干细胞联合药物治疗高血糖和糖尿病肾病 | |
CN108324737B (zh) | 脐带间充质干细胞联合药物治疗高血糖和糖尿病肾病 | |
CN110776409A (zh) | 一种印度黄檀的提取方法及提取物在抗肿瘤药物中的应用 | |
CN101711790A (zh) | 一种用于治疗肝癌的野生核桃楸树皮水提取物 | |
CN113134034A (zh) | 一种中药组合物、应用及中药制剂 | |
CN101230331A (zh) | 黄芩苷在促进骨髓间充质干细胞体外定向分化方面的用途及方法 | |
CN105663150B (zh) | 一种苯丙素类化合物及其药学上可接受的盐在制备治疗炎症性疾病的药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HENAN CHUANGXIN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZHEJIANG UNIVERSITY Effective date: 20130724 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 310027 HANGZHOU, ZHEJIANG PROVINCE TO: 456100 ANYANG, HENAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130724 Address after: Tangyin Jingjhong County of Anyang City, Henan province 456100 Road No. 718 Patentee after: HENAN CHUANGXIN PHARMACEUTICAL INDUSTRY LTD. Address before: 310027 No. 388 Tong Road, Xihu District, Zhejiang, Hangzhou, Yuhang Patentee before: Zhejiang University |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: 456100 Zhongxing Road, Tangyin industrial agglomeration area, Anyang, Henan Patentee after: Henan guangkang Pharmaceutical Co.,Ltd. Address before: Tangyin Jingjhong County of Anyang City, Henan province 456100 Road No. 718 Patentee before: HENAN CHUANGXIN PHARMACEUTICAL INDUSTRY LTD. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20160309 Address after: 456150 Zhongxing Road, Tangyin industrial agglomeration area, Anyang, Henan Patentee after: Beijing ruicaotang Sansheng Pharmaceutical Co.,Ltd. (Tangyin) Address before: 456100 Zhongxing Road, Tangyin industrial agglomeration area, Anyang, Henan Patentee before: Henan guangkang Pharmaceutical Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100811 |